Funding for this research was provided by:
Naviswiss AG
Article History
Received: 25 July 2023
Accepted: 6 October 2023
First Online: 5 December 2023
Declarations
:
: The study was embedded within a prospective observational clinical registry, for which ethical approval was obtained from a National Health and Medical Research Council certified human research and ethics committee (HREC) (Bellberry; HREC 2017-07-499). The study was also registered with the Australian New Zealand Clinical Trials Registry (ACTRN12618000317291).
: Not applicable
: C.S. is employed by EBM Analytics, which was contracted by Naviwsiss AG to assist with the completion of a protocol manuscript and data analysis for this and another study of the same device. C.S. is a shareholder in EBM Analytics. J.I. is a shareholder in Naviswiss AG. T.S.’s employer, Medivation, was contracted by Naviswiss AG to assist with the completion of the current study. T.S. additionally declares stock in Naviswiss AG.